Coherus BioSciences Files DEF 14A for Executive Compensation
Ticker: CHRS · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1512762
Sentiment: neutral
Topics: executive-compensation, sec-filing, governance
TL;DR
Coherus BioSciences DEF 14A out: Executive pay and equity awards detailed for 2024.
AI Summary
Coherus BioSciences, Inc. filed a DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and equity awards for PEO and Non-PEO NEO members, including adjustments to the fair value of awards granted in prior years. The company's principal executive office is located at 333 Twin Dolphin Dr, Suite 600, Redwood City, CA.
Why It Matters
This filing provides transparency into how Coherus BioSciences compensates its top executives and the valuation of equity awards, which can influence investor perception and executive decision-making.
Risk Assessment
Risk Level: low — DEF 14A filings are routine disclosures of executive compensation and corporate governance, not typically indicative of immediate financial risk.
Key Numbers
- 2024 — Fiscal Year (Executive compensation and equity awards are reported for this year.)
- 2023 — Fiscal Year (Comparative data for executive compensation and equity awards.)
- 2022 — Fiscal Year (Comparative data for executive compensation and equity awards.)
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Filer
- Dennis M. Lanfear (person) — Contact Person for Business and Mail Address
- 333 Twin Dolphin Dr, Suite 600 (location) — Business and Mail Address
- Redwood City, CA (location) — Business and Mail Address City and State
- 20250429 (date) — Filing Date
- 20250611 (date) — Period of Report
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide detailed information regarding the compensation of the company's named executive officers and other governance matters, as required by the Securities Exchange Act of 1934.
Who is listed as the contact person for Coherus BioSciences' business and mail address?
Dennis M. Lanfear is listed as the contact person for the business and mail address.
What is the fiscal year end for Coherus BioSciences?
The fiscal year end for Coherus BioSciences is December 31st.
What specific types of equity awards are detailed in the filing for 2024?
The filing details 'EquityAwardsValueInCompensationTableForApplicableYear' and 'EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYear' for both PEO and Non-PEO NEO members, as well as 'EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYears'.
When was Coherus BioSciences formerly known as BioGenerics, Inc.?
The company was formerly known as BioGenerics, Inc. and the name change occurred on February 10, 2011.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by Dennis M. Lanfear regarding Coherus BioSciences, Inc. (CHRS).